6The ABI in NF2: Implanting a Distorted Brainstem

FOne operation, two goals

In neurofibromatosis type 2 the ABI is almost always placed during the same operation that removes the vestibular schwannoma. The logic is unavoidable: removing the tumour from the second, or only, hearing ear will routinely sacrifice the cochlear nerve and render the patient deaf, so the electrode is laid on the cochlear nucleus before the surgeon closes, while the lateral recess is exposed. This couples a hearing-restoration procedure to a tumour resection, and the priorities of the two are not always aligned.

Two routes are used. The translabyrinthine approach drills through the inner ear to reach the cerebellopontine angle and the lateral recess, and is a familiar neurotologic corridor. The retrosigmoid approach comes from behind the sigmoid sinus and is favoured by some, especially in non-tumour cases or when there is any chance of preserving residual hearing, because it can permit tumour removal while monitoring the cochlear nerve and avoiding ABI placement if the nerve survives.[2012][2014]

TWhy the cochlear nucleus is hard to find

Placing an ABI electrode is harder than placing a cochlear-implant array because the target cannot be seen. The cochlear nucleus is small, with a visible surface area of only about one square centimetre, and it is reached indirectly through the foramen of Luschka at the end of the lateral recess of the fourth ventricle. The surgeon navigates by surrounding landmarks, the choroid plexus, the roots of the seventh, eighth and ninth nerves, rather than by direct vision of the nucleus itself, and the array is essentially placed against the presumed location.

In NF2 these landmarks are precisely what the disease disturbs. A large vestibular schwannoma compresses and rotates the brainstem, flattens the nucleus, and distorts or buries the usual reference points, so the corridor that orientates the surgeon in a normal anatomy may be displaced or scarred. Because the target is invisible, intraoperative electrically evoked auditory brainstem responses are used to confirm that stimulation reaches auditory neurons and to steer the array to its best position, while monitoring for unwanted activation of neighbouring cranial nerves.[2012][2002]

CWhy NF2 outcomes are poorer

Across series, NF2 ABI users do less well than non-tumour users. The majority of NF2 recipients gain environmental sound awareness and useful support for lip-reading, with closed-set word recognition in some, but open-set understanding without lip-reading is uncommon. Several reasons converge. The tumour itself may injure or devascularise the cochlear nucleus as it grows, and its removal can add direct mechanical or vascular damage to the very neurons the implant must drive. Brainstem distortion makes ideal placement harder, and scarring from prior surgery or radiation can degrade the interface.

An influential comparison showed that tumour patients have poorer modulation detection and speech understanding than non-tumour patients even when both can use their devices, pointing to damage at the level of the nucleus rather than simply to electrode position. This is why the same surface array can yield open conversation in a non-tumour ear with an intact nucleus yet only sound awareness in an NF2 ear. It also motivates the practice, in some centres, of first-side placement while contralateral hearing remains, so that the patient can adapt and a second side can be tried if the first disappoints.[2005][2014][2012]

CSetting realistic goals

Counselling an NF2 candidate is largely about calibrating expectations. The realistic and worthwhile goal for most is detection of environmental sound, awareness of one’s own voice, perception of speech rhythm and stress, and a meaningful boost to lip-reading, rather than telephone-quality conversation. For someone facing the loss of their last hearing ear to a growing tumour, even this represents staying connected to the world of sound, and many users wear their device daily for years and continue to improve well after activation.

Because the result is uncertain in any individual, the decision is framed around the whole clinical picture: tumour size and growth, whether useful acoustic hearing can be preserved a while longer with newer drug therapies, the patient’s motivation for prolonged rehabilitation, and acceptance that the device is an aid to communication rather than a cure. Honest counselling that an NF2 ABI typically delivers sound awareness and lip-reading support, with open-set speech a bonus rather than the expectation, is the foundation of a satisfied user.[2009][2014]